SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 375 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $51,569,776 | +9.7% | 425,423 | +3.6% | 0.01% | +11.1% |
Q2 2023 | $47,016,759 | -14.8% | 410,555 | +2.5% | 0.01% | -18.2% |
Q1 2023 | $55,189,750 | +8.8% | 400,419 | +2.2% | 0.01% | 0.0% |
Q4 2022 | $50,746,898 | +19.1% | 391,626 | +1.6% | 0.01% | +10.0% |
Q3 2022 | $42,619,000 | +48.4% | 385,553 | +0.7% | 0.01% | +66.7% |
Q2 2022 | $28,711,000 | -8.3% | 383,027 | -4.4% | 0.01% | 0.0% |
Q1 2022 | $31,297,000 | -14.4% | 400,626 | -1.4% | 0.01% | 0.0% |
Q4 2021 | $36,577,000 | +0.8% | 406,171 | +3.5% | 0.01% | 0.0% |
Q3 2021 | $36,292,000 | +20.3% | 392,427 | +1.1% | 0.01% | +20.0% |
Q2 2021 | $30,180,000 | -16.1% | 388,210 | -19.6% | 0.01% | -28.6% |
Q1 2021 | $35,983,000 | -57.0% | 482,802 | -1.6% | 0.01% | -56.2% |
Q4 2020 | $83,674,000 | +22.1% | 490,797 | +0.5% | 0.02% | +6.7% |
Q3 2020 | $68,548,000 | -10.4% | 488,125 | +2.3% | 0.02% | -16.7% |
Q2 2020 | $76,505,000 | +69.7% | 477,143 | +3.5% | 0.02% | +38.5% |
Q1 2020 | $45,078,000 | -20.3% | 460,827 | +5.1% | 0.01% | 0.0% |
Q4 2019 | $56,564,000 | +72.4% | 438,341 | +0.6% | 0.01% | +62.5% |
Q3 2019 | $32,819,000 | -35.6% | 435,735 | +29.8% | 0.01% | -33.3% |
Q2 2019 | $50,990,000 | +36.8% | 335,578 | +7.3% | 0.01% | +33.3% |
Q1 2019 | $37,267,000 | +7.3% | 312,675 | -1.8% | 0.01% | -10.0% |
Q4 2018 | $34,734,000 | -28.0% | 318,287 | +6.5% | 0.01% | -16.7% |
Q3 2018 | $48,262,000 | +22.4% | 298,814 | +0.2% | 0.01% | +20.0% |
Q2 2018 | $39,415,000 | -25.5% | 298,187 | -58.2% | 0.01% | -28.6% |
Q1 2018 | $52,881,000 | +33.1% | 713,759 | -0.1% | 0.01% | +40.0% |
Q4 2017 | $39,736,000 | +23.3% | 714,172 | +0.5% | 0.01% | +25.0% |
Q3 2017 | $32,235,000 | +51.9% | 710,642 | +12.9% | 0.01% | +33.3% |
Q2 2017 | $21,221,000 | +17.8% | 629,504 | +3.4% | 0.01% | +20.0% |
Q1 2017 | $18,021,000 | +13.2% | 608,824 | +4.9% | 0.01% | 0.0% |
Q4 2016 | $15,924,000 | -48.9% | 580,523 | +14.4% | 0.01% | -50.0% |
Q3 2016 | $31,170,000 | +223.9% | 507,567 | +0.6% | 0.01% | +233.3% |
Q2 2016 | $9,623,000 | -7.2% | 504,637 | -5.0% | 0.00% | 0.0% |
Q1 2016 | $10,373,000 | -47.9% | 531,397 | +3.0% | 0.00% | -57.1% |
Q4 2015 | $19,910,000 | +32.2% | 516,067 | +10.0% | 0.01% | +40.0% |
Q3 2015 | $15,063,000 | +8.1% | 469,114 | +2.4% | 0.01% | +25.0% |
Q2 2015 | $13,939,000 | +132.8% | 458,066 | +1.6% | 0.00% | +100.0% |
Q1 2015 | $5,988,000 | -6.9% | 450,905 | +1.4% | 0.00% | 0.0% |
Q4 2014 | $6,433,000 | -33.5% | 444,553 | -3.1% | 0.00% | -33.3% |
Q3 2014 | $9,676,000 | -30.6% | 458,589 | -2.0% | 0.00% | -25.0% |
Q2 2014 | $13,935,000 | +18.4% | 467,764 | -4.5% | 0.00% | 0.0% |
Q1 2014 | $11,765,000 | +7.8% | 489,567 | -8.6% | 0.00% | 0.0% |
Q4 2013 | $10,914,000 | -51.7% | 535,775 | +11.9% | 0.00% | -50.0% |
Q3 2013 | $22,614,000 | +186.8% | 478,806 | +130.9% | 0.01% | +166.7% |
Q2 2013 | $7,886,000 | – | 207,335 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |